Effect of GnRHa 3.75 mg subcutaneously every 6 weeks on adult height in girls with idiopathic central precocious puberty.

Liang Y, Wei H, Li J, Hou L, Zhang J, Wu W, Ying Y, Luo X

Journal of pediatric endocrinology & metabolism : JPEM1 Jul 2015Cited by 21 (Europe PMC)

PMID25719299DOI10.1515/jpem-2014-0305PepBankPUB-25719299

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

4 results from studies that gave the peptide. 4 results from people.

01HumanObservational studyEfficacy outcome
In girls with ICPP receiving triptorelin alone, final adult height was 159.81±1.20 cm.
In plain wordsIn girls with early puberty, triptorelin alone was linked to a final height of 159.81±1.20 cm.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableFinal adult height
Study
n = 17
Outcome group
Linear growth · Endocrine and hormones
Studied dose
3.75 mg every 6 weeks · subcutaneousAs given in this study (human).
Measurements
Final adult height
159.81 cm
group A, triptorelin alone
Source sentences
Summary
Final adult heights (FAHs) were 159.81±1.20 cm and 161.01±1.02 cm in group A vs. group B, which exceeded target height (THt) by 1.51±1.04 cm, 4.86±0.94 cm, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Forty females with ICPP received triptorelin 3.75 mg every 6 weeks subcutaneously in our hospital from 2002 to December 2010 and reached their final heights were enrolled.
Summary · context
These patients were treated with triptorelin alone (group A, n=17) or triptorelin+recombinant human growth hormone (rhGH) (group B, n=23).
Report a problemFND-2571929901
02HumanObservational studyEfficacy outcome
In girls with ICPP receiving triptorelin alone, final adult height exceeded target height by 1.51±1.04 cm.
In plain wordsIn girls receiving triptorelin alone, final height exceeded target height by 1.51±1.04 cm.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseFinal height above target height
Study
n = 17
Comparator
Target height
Outcome group
Linear growth · Endocrine and hormones
Studied dose
3.75 mg every 6 weeks · subcutaneousAs given in this study (human).
Measurements
Final adult height minus target height
1.51 cm
group A, triptorelin alone
Source sentences
Summary
Final adult heights (FAHs) were 159.81±1.20 cm and 161.01±1.02 cm in group A vs. group B, which exceeded target height (THt) by 1.51±1.04 cm, 4.86±0.94 cm, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Forty females with ICPP received triptorelin 3.75 mg every 6 weeks subcutaneously in our hospital from 2002 to December 2010 and reached their final heights were enrolled.
Summary · context
These patients were treated with triptorelin alone (group A, n=17) or triptorelin+recombinant human growth hormone (rhGH) (group B, n=23).
Report a problemFND-2571929903
03HumanObservational studyOther
In girls with ICPP receiving triptorelin alone, age at menarche was 11.74±0.16 years.
In plain wordsIn girls receiving triptorelin alone, age at first menstruation was 11.74±0.16 years.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableAge at menarche
Study
n = 17
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3.75 mg every 6 weeks · subcutaneousAs given in this study (human).
Measurements
Age at menarche
11.74 years
triptorelin alone (group A)
Source sentences
Summary
Ages of menarche and time to menarche from discontinuation were 11.74±0.16 vs. 12.18±0.15 years and 17.41±1.69 vs. 14.71±1.04 months in two groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Forty females with ICPP received triptorelin 3.75 mg every 6 weeks subcutaneously in our hospital from 2002 to December 2010 and reached their final heights were enrolled.
Summary · context
These patients were treated with triptorelin alone (group A, n=17) or triptorelin+recombinant human growth hormone (rhGH) (group B, n=23).
Report a problemFND-2571929909
04HumanObservational studyOther
In girls with ICPP receiving triptorelin alone, menarche occurred 17.41±1.69 months after discontinuation.
In plain wordsIn girls receiving triptorelin alone, menstruation began 17.41±1.69 months after treatment stopped.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableTime to menarche after discontinuation
Study
n = 17
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3.75 mg every 6 weeks · subcutaneousAs given in this study (human).
Measurements
Time to menarche after discontinuation
17.41 months
triptorelin alone (group A)
Source sentences
Summary
Ages of menarche and time to menarche from discontinuation were 11.74±0.16 vs. 12.18±0.15 years and 17.41±1.69 vs. 14.71±1.04 months in two groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Forty females with ICPP received triptorelin 3.75 mg every 6 weeks subcutaneously in our hospital from 2002 to December 2010 and reached their final heights were enrolled.
Summary · context
These patients were treated with triptorelin alone (group A, n=17) or triptorelin+recombinant human growth hormone (rhGH) (group B, n=23).
Report a problemFND-2571929911

Studies that did not test the peptide alone8

In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Triptorelin (Trelstar, Decapeptyl).

05HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneObservational studyEfficacy outcome
In girls with ICPP, final height minus target height differed significantly between triptorelin plus rhGH and triptorelin alone, favoring combination treatment.
In plain wordsIn girls, triptorelin plus growth hormone was linked to greater height above target height than triptorelin alone.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseFinal height minus target height
Study
n = 40
Comparator
Triptorelin alone
Outcome group
Linear growth · Endocrine and hormones
Measurements
Final adult height minus target height
1.51 cm
group A, triptorelin alone
Final adult height minus target height
4.86 cm
group B, triptorelin plus rhGH
Source sentences
Summary
The values of (FAH-THt), (FAH-PAH posttreatment) showed significant difference between the two groups (p<0.05).
3 context sentences(design, population, supporting numbers)
Summary · context
Final adult heights (FAHs) were 159.81±1.20 cm and 161.01±1.02 cm in group A vs. group B, which exceeded target height (THt) by 1.51±1.04 cm, 4.86±0.94 cm, respectively.
Summary · context
Forty females with ICPP received triptorelin 3.75 mg every 6 weeks subcutaneously in our hospital from 2002 to December 2010 and reached their final heights were enrolled.
Summary · context
These patients were treated with triptorelin alone (group A, n=17) or triptorelin+recombinant human growth hormone (rhGH) (group B, n=23).
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-2571929905
06HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneObservational studyEfficacy outcome
In girls with ICPP, final height minus posttreatment predicted height differed significantly between triptorelin plus rhGH and triptorelin alone.
In plain wordsIn girls, the difference between final and predicted height differed between triptorelin plus growth hormone and triptorelin alone.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Direction not reportedFinal height minus posttreatment predicted adult height
Study
n = 40
Comparator
Triptorelin alone
Outcome group
Linear growth · Endocrine and hormones
Source sentences
Summary
The values of (FAH-THt), (FAH-PAH posttreatment) showed significant difference between the two groups (p<0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Forty females with ICPP received triptorelin 3.75 mg every 6 weeks subcutaneously in our hospital from 2002 to December 2010 and reached their final heights were enrolled.
Summary · context
These patients were treated with triptorelin alone (group A, n=17) or triptorelin+recombinant human growth hormone (rhGH) (group B, n=23).
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-2571929906
07HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneObservational studyEfficacy outcome
In girls with ICPP receiving triptorelin plus rhGH, final adult height was 161.01±1.02 cm.
In plain wordsIn girls with early puberty, triptorelin plus growth hormone was linked to a final height of 161.01±1.02 cm.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableFinal adult height
Study
n = 23
Outcome group
Linear growth · Endocrine and hormones
Measurements
Final adult height
161.01 cm
group B, triptorelin plus rhGH
Source sentences
Summary
Final adult heights (FAHs) were 159.81±1.20 cm and 161.01±1.02 cm in group A vs. group B, which exceeded target height (THt) by 1.51±1.04 cm, 4.86±0.94 cm, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Forty females with ICPP received triptorelin 3.75 mg every 6 weeks subcutaneously in our hospital from 2002 to December 2010 and reached their final heights were enrolled.
Summary · context
These patients were treated with triptorelin alone (group A, n=17) or triptorelin+recombinant human growth hormone (rhGH) (group B, n=23).
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-2571929902
08HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneObservational studyEfficacy outcome
In girls with ICPP receiving triptorelin plus rhGH, final adult height exceeded target height by 4.86±0.94 cm.
In plain wordsIn girls receiving triptorelin plus growth hormone, final height exceeded target height by 4.86±0.94 cm.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseFinal height above target height
Study
n = 23
Comparator
Target height
Outcome group
Linear growth · Endocrine and hormones
Measurements
Final adult height minus target height
4.86 cm
group B, triptorelin plus rhGH
Source sentences
Summary
Final adult heights (FAHs) were 159.81±1.20 cm and 161.01±1.02 cm in group A vs. group B, which exceeded target height (THt) by 1.51±1.04 cm, 4.86±0.94 cm, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Forty females with ICPP received triptorelin 3.75 mg every 6 weeks subcutaneously in our hospital from 2002 to December 2010 and reached their final heights were enrolled.
Summary · context
These patients were treated with triptorelin alone (group A, n=17) or triptorelin+recombinant human growth hormone (rhGH) (group B, n=23).
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-2571929904
09HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneObservational studyEfficacy outcome
In girls with ICPP, BMI increased after triptorelin plus rhGH treatment, but there was no significant increase compared with healthy children of the same age.
In plain wordsIn girls with early puberty, BMI rose after triptorelin plus growth hormone, but with no significant increase compared with healthy children of the same age.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseBMI after combination treatment
Study
n = 23
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Body mass index (BMI) increased after treatment in group B.
Summary
However, there was no significant tendency of increase compared with healthy children at the same age.
2 context sentences(design, population, supporting numbers)
Summary · context
Forty females with ICPP received triptorelin 3.75 mg every 6 weeks subcutaneously in our hospital from 2002 to December 2010 and reached their final heights were enrolled.
Summary · context
These patients were treated with triptorelin alone (group A, n=17) or triptorelin+recombinant human growth hormone (rhGH) (group B, n=23).
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-2571929907
10HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneObservational studyEfficacy outcome
In girls receiving triptorelin plus rhGH, BMI showed no significant tendency to increase compared with healthy children of the same age.
In plain wordsIn girls receiving triptorelin plus growth hormone, BMI showed no significant upward tendency compared with healthy children of the same age.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeBMI tendency versus healthy children
Study
n = 23
Comparator
Healthy children of the same age
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
However, there was no significant tendency of increase compared with healthy children at the same age.
3 context sentences(design, population, supporting numbers)
Summary · context
Body mass index (BMI) increased after treatment in group B.
Summary · context
Forty females with ICPP received triptorelin 3.75 mg every 6 weeks subcutaneously in our hospital from 2002 to December 2010 and reached their final heights were enrolled.
Summary · context
These patients were treated with triptorelin alone (group A, n=17) or triptorelin+recombinant human growth hormone (rhGH) (group B, n=23).
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-2571929908
11HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneObservational studyOther
In girls with ICPP receiving triptorelin plus rhGH, age at menarche was 12.18±0.15 years.
In plain wordsIn girls receiving triptorelin plus growth hormone, age at first menstruation was 12.18±0.15 years.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableAge at menarche
Study
n = 23
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Measurements
Age at menarche
12.18 years
triptorelin plus rhGH (group B)
Source sentences
Summary
Ages of menarche and time to menarche from discontinuation were 11.74±0.16 vs. 12.18±0.15 years and 17.41±1.69 vs. 14.71±1.04 months in two groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Forty females with ICPP received triptorelin 3.75 mg every 6 weeks subcutaneously in our hospital from 2002 to December 2010 and reached their final heights were enrolled.
Summary · context
These patients were treated with triptorelin alone (group A, n=17) or triptorelin+recombinant human growth hormone (rhGH) (group B, n=23).
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-2571929910
12HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneObservational studyOther
In girls with ICPP receiving triptorelin plus rhGH, menarche occurred 14.71±1.04 months after discontinuation.
In plain wordsIn girls receiving triptorelin plus growth hormone, menstruation began 14.71±1.04 months after treatment stopped.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableTime to menarche after discontinuation
Study
n = 23
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Measurements
Time to menarche after discontinuation
14.71 months
triptorelin plus rhGH (group B)
Source sentences
Summary
Ages of menarche and time to menarche from discontinuation were 11.74±0.16 vs. 12.18±0.15 years and 17.41±1.69 vs. 14.71±1.04 months in two groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Forty females with ICPP received triptorelin 3.75 mg every 6 weeks subcutaneously in our hospital from 2002 to December 2010 and reached their final heights were enrolled.
Summary · context
These patients were treated with triptorelin alone (group A, n=17) or triptorelin+recombinant human growth hormone (rhGH) (group B, n=23).
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-2571929912

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.